Literature DB >> 27592087

Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases.

G J Fox1, H S Schaaf2, A Mandalakas3, E Chiappini4, A Zumla5, B J Marais6.   

Abstract

Prevention of multidrug-resistant and extensively drug-resistant tuberculosis (MDR/XDR-TB) is a top priority for global TB control, given the need to limit epidemic spread and considering the high cost, toxicity and poor treatment outcomes with available therapies. We performed a systematic literature review to evaluate the evidence for strategies to reduce MDR/XDR-TB transmission and disease progression. Rapid detection and timely initiation of effective treatment is critical to rendering MDR/XDR-TB cases non-infectious. The scale-up of rapid molecular testing has transformed the capacity of high-incidence settings to identify and treat patients with MDR/XDR-TB. Optimized infection control measures in hospitals and clinics are critical to protect other patients and healthcare workers, whereas creative measures to reduce transmission within community hotspots require consideration. Targeted screening of high-risk communities may enhance early case-detection and limit the spread of MDR/XDR-TB. Among infected contacts, preventive therapy promises to reduce the risk of disease progression. This is supported by observational cohort studies, but randomized trials are urgently needed to confirm these observations and guide policy formulation. Substantial investment in MDR/XDR-TB prevention and care will be critical if the ambitious global goal of TB elimination is to be realized.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. All rights reserved.

Entities:  

Keywords:  Elimination;; Household contacts;; Latent tuberculosis;; Mycobacterium tuberculosis;; Transmission; Tuberculosis, multidrug-resistant;

Mesh:

Year:  2016        PMID: 27592087     DOI: 10.1016/j.cmi.2016.08.024

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  16 in total

1.  Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study.

Authors:  Nishi Suryavanshi; Matthew Murrill; Amita Gupta; Michael Hughes; Anneke Hesseling; Soyeon Kim; Linda Naini; Lynne Jones; Betsy Smith; Nikhil Gupte; Rodney Dawson; Vidya Mave; Sushant Meshram; Alberto Mendoza-Ticona; Jorge Sanchez; Nagalingeswaran Kumarasamy; Kyla Comins; Francesca Conradie; Justin Shenje; Sandy Nerette Fontain; Anthony Garcia-Prats; Aida Asmelash; Supalert Nedsuwan; Lerato Mohapi; Umesh Lalloo; Ana Cristina Garcia Ferreira; Elisha Okeyo; Susan Swindells; Gavin Churchyard; N Sarita Shah
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

Review 2.  Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century.

Authors:  Jean Claude S Ngabonziza; Leen Rigouts; Gabriela Torrea; Tom Decroo; Eliane Kamanzi; Pauline Lempens; Aniceth Rucogoza; Yves M Habimana; Lies Laenen; Belamo E Niyigena; Cécile Uwizeye; Bertin Ushizimpumu; Wim Mulders; Emil Ivan; Oren Tzfadia; Claude Mambo Muvunyi; Patrick Migambi; Emmanuel Andre; Jean Baptiste Mazarati; Dissou Affolabi; Alaine N Umubyeyi; Sabin Nsanzimana; Françoise Portaels; Michel Gasana; Bouke C de Jong; Conor J Meehan
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-01-24

3.  MDR-TB in Pakistan: Challenges, efforts, and recommendations.

Authors:  Mahad Ahmed Khan; Wajeeha Bilal; Hanzla Asim; Zainab Syyeda Rahmat; Mohammad Yasir Essar; Shoaib Ahmad
Journal:  Ann Med Surg (Lond)       Date:  2022-06-17

4.  Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.

Authors:  Elsje Pienaar; Jansy Sarathy; Brendan Prideaux; Jillian Dietzold; Véronique Dartois; Denise E Kirschner; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2017-08-17       Impact factor: 4.475

5.  The Growing Importance of Tuberculosis Preventive Therapy and How Research and Innovation Can Enhance Its Implementation on the Ground.

Authors:  Anthony D Harries; Ajay M V Kumar; Srinath Satyanarayana; Pruthu Thekkur; Yan Lin; Riitta A Dlodlo; Mohammed Khogali; Rony Zachariah
Journal:  Trop Med Infect Dis       Date:  2020-04-16

Review 6.  The Diverse Search for Synthetic, Semisynthetic and Natural Product Antibiotics From the 1940s and Up to 1960 Exemplified by a Small Pharmaceutical Player.

Authors:  Jørgen J Leisner
Journal:  Front Microbiol       Date:  2020-06-12       Impact factor: 5.640

7.  Optimizing community screening for tuberculosis: Spatial analysis of localized case finding from door-to-door screening for TB in an urban district of Ho Chi Minh City, Viet Nam.

Authors:  Luan Nguyen Quang Vo; Thanh Nguyen Vu; Hoa Trung Nguyen; Tung Thanh Truong; Canh Minh Khuu; Phuong Quoc Pham; Lan Huu Nguyen; Giang Truong Le; Jacob Creswell
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

8.  Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.

Authors:  Amit Kaushik; Nicole C Ammerman; Sandeep Tyagi; Vikram Saini; Iwan Vervoort; Sophie Lachau-Durand; Eric Nuermberger; Koen Andries
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

9.  Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results.

Authors:  Kamela Charmaine Ng; Conor Joseph Meehan; Gabriela Torrea; Léonie Goeminne; Maren Diels; Leen Rigouts; Bouke Catherine de Jong; Emmanuel André
Journal:  JMIR Med Inform       Date:  2018-02-27

10.  Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.

Authors:  Greg J Fox; Cam Binh Nguyen; Thu Anh Nguyen; Phuong Thuy Tran; Ben J Marais; Steve M Graham; Binh Hoa Nguyen; Kavi Velen; David W Dowdy; Paul Mason; Warwick J Britton; Marcel A Behr; Andrea Benedetti; Dick Menzies; Viet Nhung Nguyen; Guy B Marks
Journal:  BMJ Open       Date:  2020-01-02       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.